

Alzheimer Disease

New Drugs, Markets & Companies

by

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2017

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and US, held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is CEO and consultant at Jain PharmaBiotech. Prof. Jain's 473 publications including 28 books (5 as editor + 23 as author) and 50 special reports, which cover important areas in biotechnology, cell/gene therapies and biopharmaceuticals. Recent books relevant to the nervous system include "Handbook of Neuroprotection" (Springer, 2011) and "Applications of Biotechnology in Neurology" (Springer 2013). In addition to the above, he has edited "Applied Neurogenomics" (Springer 2015).

**November 2017 (first edition in 2003)
Copyright © 2017 by**

**Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland**

**Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	17
1. Clinical Features, Epidemiology and Pathology	19
Introduction.....	19
Historical aspects.....	19
Clinical features of Alzheimer disease.....	20
Seven stages of Alzheimer disease	22
AD as a terminal illness	24
Detection of AD in the preclinical phase	24
Differentiation of AD from other dementias	24
Differentiation of AD from non-dementing disorders	26
Cerebral insufficiency and AD	26
Memory deficits and preclinical AD	26
Sleep disorders and AD.....	27
<i>Circadian rhythms and sleep in AD</i>	<i>27</i>
Mild cognitive impairment	28
Evolution of diagnostic criteria of AD	29
Revised criteria for the clinical diagnosis of AD	31
Epidemiology	32
Epidemiology of aging	32
Epidemiology of dementia	34
Epidemiology of AD	35
<i>Prevalence of AD according to age</i>	<i>35</i>
<i>Mortality in AD.....</i>	<i>35</i>
Pathophysiology of AD	35
Cerebral atrophy and neuronal loss	35
Neuritic plaques and neurofibrillary tangles	36
See-through 3D imaging of the AD brain.....	36
Sp proteins as markers of neuronal death in AD.....	37
Role of tau in the pathogenesis of AD	37
RNA-binding proteins and AD	38
Amyloid precursor protein	39
<i>Relation of APP mutations to CNS disorders.....</i>	<i>39</i>
<i>Relation of APP to Aβ deposits and pathogenesis of AD</i>	<i>40</i>
<i>APP intracellular domain</i>	<i>41</i>
<i>Role of neprilysin in Aβ degradation.....</i>	<i>41</i>
<i>Role of secretases in amyloid cascade.....</i>	<i>41</i>
<i>Role of exosomal proteins</i>	<i>43</i>
<i>Role of nicastrin</i>	<i>43</i>
Neurotoxicity of A β deposits	43
<i>Aβ production and clearance.....</i>	<i>44</i>
<i>Dysfunction of TGF-β signaling accelerates Aβ deposition</i>	<i>46</i>
<i>Interaction of Aβ with neuron-specific Na⁺/K⁺-ATPase α3 subunit</i>	<i>46</i>
<i>Relation of Aβ deposits to synaptic activity</i>	<i>46</i>
<i>Role of TMP21 in presenilin complexes and Aβ formation.....</i>	<i>46</i>
<i>Role of Aβ dimers in the pathogenesis of AD.....</i>	<i>47</i>
<i>Aβ-mediated synaptic and cognitive deficits</i>	<i>47</i>
<i>Role of dsDNA breaks in neurodegeneration due to Aβ.....</i>	<i>48</i>
<i>Structure–neurotoxicity relationships of Aβ oligomers</i>	<i>48</i>
<i>Sequence of events in neurotoxicity of Aβ</i>	<i>49</i>
Impairment of mitochondrial energy metabolism	50
<i>Aβ-binding alcohol dehydrogenase links AD to mitochondrial toxicity</i>	<i>50</i>
Neural thread protein	50
Loss of synaptic proteins	51
<i>AD and Down syndrome.....</i>	<i>51</i>
<i>Overlapping pathologies of AD and Parkinson disease</i>	<i>52</i>
<i>AD and age-related macular degeneration.....</i>	<i>52</i>
<i>Myelin hypothesis of AD.....</i>	<i>52</i>
<i>Blood-brain barrier in AD</i>	<i>52</i>
<i>Blood vessel damage in AD</i>	<i>54</i>
<i>Loss of serotonin 1A receptors in the brain.....</i>	<i>54</i>
Factors in pathogenesis of AD.....	54
<i>Astrocytes and AD.....</i>	<i>54</i>
<i>Axonal transport failure in AD</i>	<i>55</i>
<i>Cell-cycle hypothesis</i>	<i>55</i>
<i>Chronic heart failure link with AD</i>	<i>56</i>
<i>Creatine and AD.....</i>	<i>56</i>
<i>Disturbances in brain metabolism in early AD</i>	<i>56</i>

<i>Disturbances of interaction of nervous system proteins</i>	57
<i>Disturbance of lipid metabolism in the brain</i>	57
<i>DENN/MADD expression and enhanced pro-apoptotic signaling in AD</i>	57
<i>Dopamine and AD</i>	57
<i>Gonadotrophins and AD</i>	58
<i>Glutamate transport dysfunction in AD</i>	58
<i>Herpes simplex virus type 1 and AD</i>	59
<i>Innate immune system and AD</i>	60
<i>Insulin, diabetes and AD</i>	60
<i>Mechanisms underlying cognitive deficits in AD</i>	61
<i>Microglia and AD</i>	62
<i>Monoamine oxidase and AD</i>	62
<i>Neuroinflammation and AD</i>	63
<i>Neurotransmitter deficits</i>	64
<i>Neurotrophic factors</i>	65
<i>NF-κB signaling and the pathogenesis of neurodegeneration</i>	65
<i>Nitric oxide and AD</i>	65
<i>Nogo receptor pathway</i>	68
<i>Oxidative stress and AD</i>	68
<i>Prostaglandins and AD</i>	70
<i>Quinolinic acid and AD</i>	70
<i>Retromer deficiency</i>	70
<i>Serotonin and AD</i>	71
Spread of neurodegeneration.....	71
<i>Synaptic failure in AD</i>	71
<i>Transmission of AD</i>	72
<i>Ubiquitin-proteasome system in pathogenesis of AD</i>	73
Risk factors in the etiology of AD.....	74
<i>Aging and developmental abnormalities of the cholinergic system</i>	74
<i>Cholesterol, dietary lipids, and Aβ</i>	75
<i>Exposure to magnetic fields</i>	76
<i>Family history of AD</i>	76
<i>Homocysteine and AD</i>	76
<i>Hypertension and AD</i>	77
<i>Level of education/type of job and risk of AD</i>	77
<i>Metals and AD</i>	78
<i>Obesity</i>	79
<i>Proneness to psychological distress and risk of AD</i>	80
<i>Reduced muscle strength</i>	80
<i>Sleep deprivation</i>	80
<i>Traumatic brain injury and AD</i>	81
<i>Vascular risk factors for AD</i>	82
<i>Vitamin B12 and folate</i>	83
AD versus non-dementing changes in the aging brain.....	84
AD and cognitive impairment with aging.....	84
Pathomechanism of memory impairment and AD.....	84
Concluding remarks on pathophysiology of AD.....	85
Genetics of AD	86
Familial AD.....	87
<i>Molecular genetics of familial AD</i>	87
<i>Presenilins and calcium channel pathogenesis of familial AD</i>	88
<i>Presenilin-1 mutations and familial AD</i>	88
Late onset AD.....	89
Genomics of AD	89
Introduction to genomics.....	89
Genes associated with Alzheimer disease.....	90
<i>AlzGene database</i>	91
<i>ApoE gene</i>	91
<i>ApoE genotype and nitric oxide</i>	93
<i>ApoE genotype modulates AD phenotype</i>	93
<i>APOE genotype and age-related myelin breakdown</i>	94
<i>ApoE receptor interaction with NMDA receptor</i>	94
<i>ApoE and ApoER2</i>	94
<i>ApoE receptor LR11 as regulator of Aβ</i>	95
<i>Arctic mutation</i>	95
<i>BCHE gene</i>	95
<i>CALHM1 polymorphism and AD</i>	96
<i>CLU, CRI and PICALM</i>	96
<i>CYP46 and risk for AD</i>	96
<i>DAPK1 gene variants and AD</i>	97
Genetic variants associated with early-onset AD.....	97

Genetic variants associated with late-onset AD	97
<i>ApoE</i> polymorphisms associated with LOAD	97
Copy number variation (CNV) in LOAD	98
<i>LRRTM3</i> as a candidate gene for AD	98
<i>MTHFD1L</i> gene variant associated with AD	98
Mutation in <i>APP</i> gene with protective effect against AD	99
<i>OGG1</i> mutations associated with AD	99
<i>SORL1</i> gene in AD	99
<i>TOMM40</i> gene and risk of AD	100
<i>TREM2</i> variants in AD	100
International Genomics of Alzheimer's Project	100
Sequencing in Alzheimer disease	101
Molecular neuropathology	103
Role of microRNAs in AD	103
DNA methylation in AD	104
AD as a polygenic disorder	105
Proteomics of AD	105
Introduction	105
Application of proteomic technologies to study AD	105
Protein misfolding in AD	107
Common denominators of AD and prion diseases	108
2. Diagnostic Procedures for Alzheimer Disease	109
Importance of the diagnosis of Alzheimer disease	109
Methods of diagnosis of AD	109
Self-administered olfactory test	110
Neuropsychological testing	110
Assessment and evaluation	111
7-minute screen	111
15-point risk index	112
Activities of Daily Living	112
Alzheimer Disease Cooperative Study	112
CDR-SOB score	112
Clinician's Interview-Based Impression of Change	113
DETECT™ System	113
Measurement of aggregation in anterior segment of the eye	113
Resource Utilization in Dementia Battery	113
SymptomGuide™	113
Electrophysiology	114
Quantitative EEG for investigation of early AD	114
EEG-based bispectral index	114
Event-related potentials	114
Correlation of electrical activity of the brain with cognition	115
Early detection of cataract associated with AD	115
Retinal imaging to detect A β deposits	115
Laboratory methods for diagnosis of AD	116
Monitoring of synthesis and clearance rates of A β in the CSF	117
Molecular diagnostics for AD	117
Genetic tests for AD	118
<i>ApoE</i> genotyping	119
Gene expression patterns in AD	119
Monoclonal antibody-based in vitro diagnosis of AD from brain tissues	119
Multi-tissue RNA signature of aging as diagnostic for AD	119
Biomarkers of AD	120
The ideal biomarker for AD	122
CSF biomarkers of AD	122
CSF sulfatide as a biomarker for AD	122
Glycerophosphocholine as CSF biomarker in AD	123
Protein biomarkers of AD in CSF	123
Tau proteins in CSF	125
Tests for the detection of A β in CSF	125
Tests combining CSF tau and A β	126
Concluding remarks about CSF biomarkers of AD	126
Urine tests for AD	127
Blood tests for AD	127
Blood A β levels	127
Blood test for AD based on heme oxygenase-1	128
Blood test for AD based on RNA hybridization	128
GSK-3 elevation in white blood cells	128
Lipid biomarkers for preclinical detection of AD	129
Lymphocyte Proliferation Test	129

<i>Metabolomic biomarker profiling</i>	129
<i>MGAT3 as biomarker for prognosis of AD</i>	130
<i>MicroRNA-based test for AD</i>	130
<i>Protein kinase C in red blood cells</i>	130
<i>Sphingolipids</i>	130
<i>Tests based on protein biomarkers in blood</i>	131
A skin test for early detection of AD	131
Saliva-based tests for AD	132
<i>Saliva Aβ42 level as a biomarker of AD</i>	132
Nanotechnology to measure A β -derived diffusible ligands	132
Simultaneous measurement of several biomarkers for AD	133
Nutritional biomarkers in plasma of AD patients	133
Plasma biomarkers of drug response in AD	134
A serum protein-based algorithm for the detection of AD	134
Concluding remarks about biomarkers for AD	134
Imaging in AD	135
Computed tomography	135
Magnetic resonance imaging	135
<i>Arterial spin labeling with MRI</i>	136
<i>Magnetic resonance microscopy</i>	136
<i>Magnetic resonance spectroscopy</i>	136
Single photon emission computed tomography and modifications	137
Positron emission tomography	138
In vivo imaging of A β deposits by PET	139
<i>Pittsburgh compound B and PET</i>	140
<i>Florbetapir-PET</i>	141
<i>Florbetaben-PET</i>	142
<i>Flutemetamol-PET</i>	142
<i>Future prospects of the PET imaging in AD</i>	142
In vivo detection of A β plaques by MRI	143
Imaging agents for A β and neurofibrillary tangles	143
Targeting of a chemokine receptor as biomarker for brain imaging	144
Radiiodinated clioquinol as a biomarker for A β	144
Imaging neuroinflammation in AD	145
Preclinical diagnosis of AD	145
<i>Correlation of imaging with CSF biomarkers for early detection of AD</i>	146
Meta-analysis of literature on imaging in AD	146
Alzheimer Disease Neuroimaging Initiative	146
Computer aided diagnosis systems for AD based on imaging data	147
Concluding remarks on imaging for diagnosis of AD	148
Diagnosis of MCI and prediction of AD	148
Diagnosis of MCI	148
<i>Computer-Administered Neuropsychological screen for MCI</i>	148
<i>Infrared eye-tracking technology to detect MCI</i>	149
<i>MRI for detection of MCI</i>	149
<i>PET for detection of MCI</i>	149
<i>Role of APOE genotype in early MCI</i>	150
Presymptomatic detection of AD	150
<i>Biomarker changes in autosomal dominantly inherited AD</i>	151
<i>Blood test for preclinical diagnosis of AD</i>	151
<i>Gait analysis during cognitive tasks</i>	151
PredictAD project	152
Prediction of AD in patients with MCI	152
<i>Biochemical biomarkers in CSF for prediction of AD</i>	152
<i>Clinical and biochemical biomarkers for profiling prodromal AD</i>	153
<i>Combination of MMSE and a memory test for prediction of AD</i>	153
<i>Plasma protein biomarkers of conversion of MCI to AD</i>	153
<i>Structural MRI biomarkers for prediction of AD</i>	153
<i>Magnetoencephalography for detection of MCI and AD</i>	154
<i>MRI-based index to measure the severity of AD in MCI</i>	154
<i>Concluding remarks about prediction of AD in MCI</i>	154
Criteria for diagnosis of AD	155
Role of biomarkers in diagnosis of AD dementia	156
Ethical aspects of diagnostics for AD	157
Genetic testing for AD	157
Ethical issues of brain imaging in AD	158
Monitoring of treatment of AD	158
<i>Monitoring treatment of mixed AD and vascular dementia</i>	158
Companies involved in diagnosis of AD	159
3. Management of Alzheimer Disease	161

Introduction.....	161
Cholinergic approaches	161
Mechanism of action of cholinesterase inhibitors	162
Choline and lecithin	163
Donepezil	164
Rivastigmine	165
Galantamine.....	166
Duration of treatment with ChE inhibitors.....	167
Comparative studies of ChE inhibitors	167
Donepezil versus rivastigmine	168
Donepezil versus galantamine	168
Combination of cholinesterase inhibitors and a cholinergic precursor	168
An assessment and future prospects of anticholinergic therapies.....	169
Neuroprotection in Alzheimer's disease	170
Memantine	170
<i>Pharmacology of memantine</i>	170
<i>Clinical trials of memantine</i>	171
<i>Combination of memantine with ChE inhibitors</i>	173
Monoamine oxidase inhibitors.....	174
<i>Selegiline</i>	174
Synaptoprotection in AD	174
Drugs for noncognitive symptoms in AD	175
Antidepressants	175
Antipsychotics	175
ChE inhibitors for behavioral and psychological disorders in AD.....	176
Concluding remarks and other drugs for agitation in AD.....	176
Sensory stimulation.....	177
Non-pharmacological treatments of AD	177
Cerebrospinal fluid shunting	177
Deep brain stimulation.....	178
Exposure of the brain to electromagnetic fields for treatment of AD.....	179
<i>Application of electrical fields for improvement of cerebral function</i>	179
<i>High-frequency electromagnetic field treatment of AD</i>	179
<i>Transcranial magnetic stimulation</i>	180
Mental training for management of memory loss in AD	180
Microchip-based hippocampal prosthesis for AD	180
Omental transposition	181
Photo-induced inhibition of A β accumulation in AD	181
Scanning ultrasound for removal of A β	181
Vagal nerve stimulation	182
Nutritional therapies for AD	182
Axona.....	182
Cocktail of dietary supplements for AD	182
Docosahexaenoic acid	183
Magnesium	184
Nicotinamide for the treatment of AD	185
Omega-3 fatty acids.....	185
Preventing decline of mental function with aging and dementia	186
Prevention of Alzheimer disease	187
<i>Mental training</i>	188
<i>Physical exercise</i>	188
<i>Higher level of conscientiousness and decreased risk of AD</i>	189
Nutritional factors in prevention of AD and MCI.....	189
<i>Black and green teas</i>	190
<i>Caffeine</i>	190
<i>Caloric restriction</i>	191
<i>Cinnamon</i>	191
<i>Cocoa flavonol consumption</i>	191
<i>Grapes and red wine</i>	191
<i>Vitamin D and docosahexaenoic acid</i>	193
Drugs to prevent Alzheimer disease	193
Preimplantation genetic diagnosis of inherited Alzheimer disease	193
Presymptomatic detection of AD	193
Management of mild cognitive impairment	194
Slowing the progression of MCI to AD	194
Management of Down syndrome.....	195
Guidelines for use of anti-dementia drugs in clinical practice	196
Donepezil and/or memantine.....	196
General care of the Alzheimer disease patients	197
Strategies for the management of Alzheimer disease	197

4. Research in Alzheimer Disease	199
Introduction.....	199
Animal models of Alzheimer disease	199
Lesional models	199
<i>Cerebroventricular injection of Aβ in rats</i>	<i>199</i>
<i>Lentiviral vector-based models of amyloid pathology</i>	<i>200</i>
<i>AAV-mediated gene transfer to increase hippocampal Aβ</i>	<i>200</i>
Transgenic mouse models	200
<i>Quantitative assessment of amyloid load in transgenic models.....</i>	<i>201</i>
<i>In vivo magnetic resonance microimaging in transgenic models of AD</i>	<i>202</i>
<i>Transgenic model of AD with suppression of Aβ production.....</i>	<i>202</i>
<i>Transgenic AD11 anti-NGF mice.....</i>	<i>202</i>
<i>Genetically altered mice with deficiency of vesicular ACh transporter.....</i>	<i>203</i>
<i>Limitations of mouse models of Alzheimer disease</i>	<i>203</i>
<i>Improved mouse models of AD expressing human genes</i>	<i>204</i>
Cholesterol-fed rabbits as models for AD.....	204
Canine dementia as model for AD	204
Zebrafish model for AD	205
Transgenic invertebrate models of Alzheimer disease	206
<i>Drosophila model of AD</i>	<i>206</i>
<i>Caenorhabditis elegans Alzheimer disease model</i>	<i>206</i>
Correlation of studies in animal models and human clinical trials.....	207
Cell systems for AD research	208
In vitro neuronal cell Lines	208
Single-gene expression system for use in cell culture	208
Stem cells for testing efficacy of AD drugs.....	208
Transgenic cells	209
In silico models.....	209
Estimation of progression rates of Alzheimer disease.....	210
Clinical trial methods in Alzheimer disease	210
Molecular imaging as a guide to drug development	211
Use of MRI and PET in clinical trials	211
Cognitive-function assessment in clinical trials.....	212
Clinical trials in mild cognitive impairment.....	212
Research in AD as a basis for future therapies.....	213
Use of microarrays for studying pathogenesis of AD	213
Computational brain mapping in AD	213
Study of neurogenesis in AD.....	213
Study of 3D structure of A β	213
Solid-state NMR to study precursors of A β	214
Research in Alzheimer disease at academic centers	214
Role of NIH in AD research.....	214
NIH Clinical Trials Database for AD.....	214
Alzheimer Research Consortium.....	214
The National Institute on Aging and AD research.....	215
5. Drug Discovery & Development for Alzheimer Disease	217
Introduction.....	217
Categories of drugs in development for AD	217
Memory-enhancing drugs	219
Enhancing memory by drugs that block eIF2 α phosphorylation	219
Drugs based on cholinergic approaches	219
AP2238.....	220
Butyrylcholinesterase inhibitors	220
Donepezil-tacrine hybrids.....	220
Drugs modulating gamma-aminobutyric acid receptors	221
Ganstigmina	221
Methanesulfonyl fluoride	221
Muscarinic receptor modulators	222
<i>Muscarinic M1 agonists</i>	<i>222</i>
<i>Muscarinic M2 antagonists.....</i>	<i>223</i>
Nicotine and nicotinic receptor modulators	223
<i>Nicotine</i>	<i>223</i>
<i>Nicotinic receptor modulators</i>	<i>224</i>
<i>GTS21</i>	<i>226</i>
<i>Ispronicline</i>	<i>227</i>
<i>JWB1-84-1</i>	<i>227</i>
Neuropeptide/neurotransmitters.....	227
Somatostatin release enhancers	227
Glutamate receptor modulators	228
Physiology and pharmacology of glutamate receptors	228

NMDA receptor ion channel complex.....	228
Metabotropic glutamate receptors.....	229
Glutamate receptor modulators as potential therapeutics for AD.....	230
<i>N2OC</i>	231
<i>AMPA modulators</i>	231
Glutamate release inhibitors.....	232
<i>INI-0602</i>	232
Drugs affecting multiple neurotransmitters.....	232
Enzaculin.....	232
RS-1259.....	232
Lecozotan.....	232
Vaccines for AD.....	233
Active immunization with A β	233
<i>AN-1792 vaccine</i>	233
<i>Complications in clinical trials with AN-1792</i>	234
<i>Effects of Aβ vaccine on the brain</i>	234
Strategies to avoid undesirable effect of A β vaccination.....	235
Passive immunization in AD.....	236
<i>Passive immunization with MAbs</i>	236
<i>Clinical trials of MAbs in AD</i>	237
<i>Delivery of the passive antibody directly to the brain</i>	238
<i>Systemic injection of MAbs to treat AD</i>	239
Combination of A β immunotherapy and CD40-CD40L blockade.....	239
Shaping the immune responses elicited against A β	239
Delivery of AD vaccines.....	240
<i>Gene vaccination</i>	240
<i>Modified Aβ nasal vaccine</i>	241
<i>Transdermal Aβ vaccination</i>	241
Other vaccines for AD.....	241
<i>Nasal vaccination with Proteosome™ adjuvant</i>	242
<i>T cell vaccination with glatiramer acetate adjuvant</i>	242
Early start of immunotherapy for clearing A β plaques.....	242
Reversal of cholinergic dysfunction by anti-A β antibody.....	242
Immune modulation via Toll-like receptors to reduce A β	243
Mechanisms by which A β antibodies reduce amyloid accumulation in the brain.....	243
Perspectives on vaccines for AD.....	244
Companies involved in AD vaccines.....	246
Inhibition of amyloid precursor protein aggregation.....	246
Secretase modulators.....	246
<i>Neuroprotection by α-secretase cleaved APP</i>	247
<i>Inhibitors of β-secretase</i>	248
<i>Inhibitors of γ-secretase</i>	249
Amyloid-derived diffusible ligands.....	251
GABA receptor modulation by etazolate and APP processing.....	251
Depletion of serum amyloid P.....	251
Drugs that inhibit the formation of Aβ.....	251
22R-hydroxycholesterol.....	252
Acylaminopyrazole.....	252
Cadmium telluride nanoparticles prevent A β fibril formation.....	252
Cannabinoids.....	253
Chelation therapy for AD.....	253
<i>Clioquinol and PBT2</i>	254
<i>Copper chelation by FKBP52</i>	255
<i>Zinc chelation from amyloid plaques</i>	256
<i>Next generation multifunctional chelating agents for AD</i>	256
Heparin and its derivatives.....	257
<i>A reassessment of the role of heparin in AD</i>	257
<i>Enoxaparin</i>	257
<i>Heparan sulfate</i>	257
Imatinib mesylate.....	258
Laminin.....	258
Masitinib.....	258
NSAIDs.....	259
<i>Flurbiprofen analogs with Aβ42-lowering action</i>	259
<i>Nitric oxide-donating NSAIDs</i>	260
<i>In vivo demonstration of the effects of NSAIDs on brain in AD</i>	261
Paclitaxel.....	261
Phenserine.....	261
<i>Tolserine</i>	262
Platinum-based inhibitors of A β	262
Retro-inverso peptide inhibitor.....	262

Scyllo-cyclohexanehexol	263
Selective serotonin reuptake inhibitor	263
Small molecule drug discovery for inhibiting A β aggregation	263
Trojan-horse approach to prevent build-up of A β aggregates	264
Ubiquitin C-terminal hydrolase L1	264
Drugs to prevent the formation of NFTs	264
Tau suppression	265
Anthraquinones	265
Anti-tau antibodies	266
Tau aggregation inhibitor rember™	266
LMTX®	266
Microtubule stabilizers	266
ApoE4 as a therapeutic target in AD	266
Strategies to prevent deposits and enhance clearance of Aβ	267
4,5-dianilinophthalimide for disruption of A β ₁₋₄₂ fibrils	268
ABCA1 overexpression to lower amyloid deposits	268
ANAVEX 2-73	269
Beta-sheet breakers	269
Bexarotene	269
Blocking ApoE/A β interaction to reduce A β plaques	270
CD33 inhibitors	270
Clearance of A β across the blood-brain barrier	270
Enhanced PKC ϵ activity promotes clearance of A β	271
Galantamine-induced A β clearance	271
Hemopheresis	271
Inhibitors of A β dehydrogenase	272
Intravenous immune globulin	272
Monoclonal antibodies for removal of A β	273
<i>Crenezumab</i>	273
<i>Gantenerumab</i>	273
<i>Solanezumab</i>	274
Nanotechnology for removal of A β deposits	274
Role of matrix metalloproteinases in clearance of A β	274
SAN-61 for cleavage of fibril and soluble amyloid	275
Serum amyloid P component depletion	275
Small molecule DAPH for clearance of amyloid	275
Companies developing Aβ-directed therapeutics for AD	276
Nootropics	277
Acetyl-L-carnitine	277
Cerebrolysin	278
Ergot derivatives	278
<i>Lisuride</i>	278
<i>Dihydroergocryptine</i>	279
Neuroprotective effect drugs not primarily developed for AD	279
Antiepileptic drugs	280
<i>Lamotrigine</i>	280
<i>Levetiracetam</i>	280
Antiinflammatory and antimicrobial drugs	280
<i>Dapsone</i>	280
<i>Antimicrobial drugs against C. pneumoniae</i>	281
<i>PPAR-gamma agonists</i>	281
Antidiabetic drugs	281
<i>Insulin</i>	282
<i>Metformin</i>	282
<i>Rosiglitazone</i>	282
<i>Pioglitazone</i>	283
Antihypertensive drugs	283
<i>Angiotensin-converting enzyme inhibitors</i>	283
<i>Angiotensin receptor blockers</i>	283
Bexarotene	284
Dimebon	284
Drugs acting on estrogen receptors	285
<i>Estrogen</i>	285
<i>Raloxifene</i>	286
Inhibitors of neuroinflammation	286
<i>Ceramide</i>	286
<i>CSP-1103</i>	287
<i>Cyclophosphamide</i>	287
<i>Etanercept</i>	287
<i>Fingolimod</i>	288
<i>Interferon beta-1a</i>	288

<i>MW01-5-188WH</i>	288
Neurosteroids	289
<i>Pregnenolone sulfate</i>	289
<i>Dehydroepiandrosterone</i>	289
Lithium	290
MAO-B inhibitors	290
<i>Ladostigil tartrate</i>	290
<i>Memoquin</i>	291
Methylene blue	291
Nilotinib	291
Nimodipine.....	292
Rapamycin	292
Saracatinib.....	292
Statins.....	293
Testosterone	293
Valproic acid.....	294
Future prospects of neuroprotection in AD.....	295
<i>Targeting Cdk5 pathway</i>	295
Antioxidants	296
Colostrinin	296
Curcumin	296
Dehydroascorbic acid.....	297
Reservatrol	298
Synthetic catalytic scavengers	298
Vitamins.....	299
Vitamin E as antioxidant	299
Vitamin B for lowering homocysteine	299
Folic acid	299
Aminopyridazines	300
Nanobody-based drugs for AD	300
Nitric oxide based therapeutics for AD.....	300
Nitric oxide mimetics	300
iNOS inhibitors for AD.....	301
Novel drugs for AD from natural resources	301
Berberine chloride.....	302
Centella asiatica.....	302
Ginko biloba	303
Huperzine-A	304
Hyperforin.....	304
Melissa officinalis	305
Nostocarboline derived from cyanobacteria	305
PTI-00703.....	305
Salvia.....	305
Securinega suffruticosa	306
Withania somnifera	306
ZT-1.....	306
Cholesterol and AD	307
ACAT inhibitors	308
Role of gene for cholesterol ester transfer protein	308
Cholesterol 24S-hydroxylase as a drug target for AD.....	309
Selectively increase of ApoA-I production.....	309
Neurotrophic factors	309
Brain derived neurotrophic factor	309
Insulin-like growth factor-1	310
Nerve growth factor	310
Neotrofin (AIT-082).....	311
Limitations of the use of NTFs for AD.....	311
Role of serotonin modulators in AD	312
Xaliproden	312
5-HT _{1A} receptor antagonists	312
5-HT ₆ antagonists	312
5-HT ₄ receptor agonists.....	313
<i>PRX-03140</i>	313
<i>Donecopride</i>	314
Restoration of factors deficient in the aging brain	314
Reversal of cognitive impairment in aging by activation of creb protein.....	314
Reversal of cognitive impairment in aging by GDF11 protein	314
Restoration of repressor element 1-silencing transcription factor.....	315
Cell therapy for AD.....	315
Stem cell transplantation for AD	315
<i>Potential benefits of grafting NSCs in AD</i>	316

<i>NSCs improve cognition in AD via BDNF</i>	316
<i>Drugs for enhancing neuronal differentiation of implanted NSCs</i>	316
Choroid plexus epithelial cells for AD	317
Implantation of encapsulated cells for delivering NGF	317
Gene therapy for AD	317
ApoE gene therapy.....	318
<i>APPsa gene transfer for rescuing synaptic failure in AD</i>	318
FGF2 gene transfer in AD.....	318
Humanin gene therapy	318
Nephrilysin gene therapy	319
NGF gene therapy	319
Targeting plasminogen activator inhibitor type-1 gene.....	320
Antisense approaches to AD	320
RNAi approaches to AD	321
Combined therapeutic approaches to AD	322
Drug delivery for Alzheimer disease	322
Delivery of biologicals across the BBB.....	323
Delivery of thyrotropin-releasing hormone analogs by molecular packaging.....	324
Nanoparticle-based drug delivery for Alzheimer's disease.....	324
Transdermal drug delivery in Alzheimer's disease.....	325
<i>Transdermal rivastigmine</i>	325
Intranasal delivery of therapeutics for AD	325
<i>Intranasal delivery of tacrine</i>	325
<i>Intranasal delivery of nerve growth factor to the brain</i>	326
Circadian rhythms and timing of cholinesterase inhibitor therapy	326
Clinical trials for AD	326
Drugs for AD that were discontinued in clinical trials.....	333
Monitoring of cognitive function during clinical trials	336
Concluding remarks on clinical trials of AD	336
Drug discovery for AD	337
Drugs acting on signaling pathways.....	337
<i>Activation of GTPase signaling by Cytotoxic Necrotizing Factor 1</i>	337
<i>Drugs to reverse inhibition of the PKA/CREB pathway in AD</i>	337
<i>Inhibition of the CD40 signaling pathway</i>	338
<i>JNK pathway as a target</i>	338
<i>Mitogen-activated protein kinase pathway as target</i>	338
<i>Protein kinase C activators</i>	339
Electrophysiological detection of drug target for neuroprotection in early AD	339
Genomics-based drug discovery.....	339
High through screening for AD drug candidates	340
New chemical entities for AD by combining galantamine and memantine	340
Novel rivastigmine-hydroxycinnamic acid hybrids for AD.....	340
Novels targets/receptors for AD drug discovery	341
<i>Activation of cerebral Rho GTPases</i>	341
<i>Activators of insulin-degrading enzyme</i>	341
<i>Blockade of TGF-β-Smad2/3 signaling in peripheral macrophages</i>	341
<i>Calcium channel blockers</i>	342
<i>Calpain inhibitors</i>	342
<i>Casein kinase 1</i>	343
<i>Cyclin-dependent kinase-5</i>	343
<i>Drugs against arginine deprivation and immune suppression in AD</i>	343
<i>Heat shock protein 90 inhibitors</i>	344
<i>Histone deacetylase inhibitors</i>	344
<i>Inhibition of PDK1 to slow progression of both AD and prion disease</i>	344
<i>Melatonin</i>	345
<i>Neurotrophic compound J147</i>	345
<i>NF-κB inhibitors</i>	346
<i>Kinases and phosphatases as targets for AD therapeutics</i>	346
<i>Neutral sphingomyelinase inhibitors</i>	347
<i>Phosphodiesterase inhibitors</i>	347
<i>Pin 1 as a target in AD</i>	347
<i>Protein phosphatase 5 as a neuroprotective in AD</i>	348
<i>Single drugs for multiple targets in AD</i>	348
<i>Src homology-containing protein-1 inhibitors</i>	348
<i>Targeting GABAergic system</i>	349
<i>TSPO ligands</i>	349
Proteomics and drug discovery for AD	349
Small molecule compounds binding to neurotrophin receptor p75NTR.....	350
<i>Targeting Vav in tyrosine kinase signaling pathway</i>	351
<i>LM11A-31 as p75NTR ligand</i>	351
Pharmacogenomics of Alzheimer disease	352

Biomarkers and companion diagnostics for AD	352
Personalized therapy of AD	352
Genotyping and AD therapeutics	353
Regulatory aspects of drug development for AD	354
EMA guidelines for drug development for AD	354
FDA guidelines for drug development for AD.....	355
Concluding remarks and future of AD research	356
Future for AD therapeutics	356
6. Markets & Finances of AD Care	359
Introduction.....	359
Pharmacoeconomics of treatment of AD	359
Quality of Life in relation to economics of AD	359
Costs associated with Alzheimer disease	359
Pharmacoeconomics of donepezil	360
Pharmacoeconomics studies using rivastigmine	360
Pharmacoeconomics studies using galantamine	361
Pharmacoeconomics studies using memantine.....	361
Patterns of AD care in major markets	361
Care of AD patients in the US	362
<i>Cost of care.....</i>	362
<i>Medicare and AD.....</i>	363
<i>Patterns of practice in AD care.....</i>	364
<i>Opinions of physicians' organizations on drugs for dementia</i>	364
Care of AD patients in the UK	365
<i>Cost of care.....</i>	365
<i>Patterns of practice in AD care.....</i>	365
<i>NICE recommendations to NHS.....</i>	366
Care of AD patients in Germany	367
Care of AD patients in France	368
Care of AD patients in Italy	368
Care of AD patients in Spain.....	368
Care of AD patients in Japan	369
Markets for AD diagnostics	369
Markets for AD therapeutics	369
Geographical markets for AD	369
Markets for currently approved drugs for AD	370
Markets for generic AD drugs	371
Statins.....	371
Future growth of AD market	371
Limitations of AD drug development by the biotechnology industry	372
Unmet needs in the management of AD	373
Drivers of AD markets	374
Increase of the aged populations	374
Increase in the number of approved drugs for AD	374
Limitations of the current therapies	375
Improvements in diagnosis	375
Increasing awareness of the disease.....	375
7. Companies	377
Introduction.....	377
Profiles of companies.....	377
Collaborations.....	527
8. References.....	531

Tables

Table 1-1: Historical landmarks relevant to Alzheimer disease	19
Table 1-2: Clinical features of Alzheimer disease.....	20
Table 1-3: Non-Alzheimer dementias.....	25
Table 1-4: A guide to evaluation for MCI due to AD.....	29
Table 1-5: NINCDS-ADRDA Criteria for diagnosis of Alzheimer disease	30
Table 1-6: 2011 Revised criteria for diagnosis of dementia due to Alzheimer Disease	31
Table 1-7: Relation of mutations in amyloid precursor protein to CNS disorders	39
Table 1-8: Risk factors for Alzheimer's disease	74
Table 1-9: Genes linked to AD	90
Table 1-10: Abnormalities of expression of brain proteins in Down's syndrome and AD.....	106
Table 2-1: Classification of methods of diagnosis of Alzheimer disease	109
Table 2-2: Neuropsychological test batteries and scales for Alzheimer's disease	110

Table 2-3: Available molecular diagnostic tests for Alzheimer disease.....	118
Table 2-4: Biomarkers of AD in blood and CSF	120
Table 2-5: Characteristics of an ideal biomarker for Alzheimer disease	122
Table 2-6: Role of biomarkers in diagnosis of AD dementia	157
Table 2-7: Companies involved in the diagnosis/monitoring of Alzheimer disease	159
Table 3-1: Classification of treatments for Alzheimer disease	161
Table 3-2: Cholinergic approaches used in the treatment of Alzheimer disease	162
Table 3-3: Categories of neuroprotective agents for Alzheimer disease	170
Table 3-4: Strategies for prevention of Alzheimer disease	187
Table 3-5: Guidelines for the treatment of dementia	196
Table 4-1: Transgenic mouse models of Alzheimer disease.....	200
Table 4-2: Correlation of studies in animal models with human clinical trials	207
Table 5-1: Classification of therapies in development for Alzheimer disease	217
Table 5-2: Drugs for AD targeting nACh receptors	226
Table 5-3: Ionotropic glutamate receptors	228
Table 5-4: Classification of mGluRs	228
Table 5-5: Glutamate receptor modulators as potential therapeutic agents in AD	230
Table 5-6: Companies involved in developing vaccines for AD	246
Table 5-7: Preclinical studies of secretase modulators	247
Table 5-8: Secretase modulators in clinical trials	247
Table 5-9: Companies developing A β -directed therapeutics for AD	276
Table 5-10: Innovative neuroprotective approaches for Alzheimer disease	279
Table 5-11: Herbal therapies for AD	302
Table 5-12: Novel drug delivery methods for Alzheimer disease therapies.....	323
Table 5-13: Clinical trials in Alzheimer disease	327
Table 5-14: Discontinued, failed or inconclusive clinical trials of Alzheimer disease.....	333
Table 6-1: Direct and indirect costs associated with Alzheimer disease	362
Table 6-2: Prevalence of AD in major markets 2016-2026	370
Table 6-3: AD market values from 2016-2026 in major world markets	370
Table 6-4: Markets for currently approved AD drugs 2016-2026	371
Table 6-5: Potential markets for drugs in development 2016-2026.....	372
Table 6-6: Limitations of AD drug development by the biotechnology industry.....	372
Table 6-7: Factors that drive AD markets.....	374
Table 7-1: Major players in Alzheimer's disease therapeutics.....	377
Table 7-2: Collaborations relevant to Alzheimer disease	527

Figures

Figure 1-1: Percentages of world population of people over the age of 65 according to more developed and less developed portions – 2000 to 2050.	32
Figure 1-2: Correlation between aging and AD in the US from 2000 to 2020	33
Figure 1-3: Prevalence of different types of dementia.....	34
Figure 1-4: A β deposits in the brain	44
Figure 1-5: Mechanisms of A β clearance	45
Figure 1-6: Pathways for A β -induced nerve cell death	49
Figure 1-7: Insulin signaling in Alzheimer disease and diabetes	61
Figure 1-8: Nitric oxide neurotoxicity and neuroprotection in relation to Alzheimer disease	67
Figure 1-9: Oxidative stress and Alzheimer disease	69
Figure 1-10: Role of proteasome inhibition in A β generation and neurodegeneration	73
Figure 1-11: Cholesterol-related pathways to AD	75
Figure 1-12: Pathomechanism of AD	86
Figure 3-1: Metabolism of acetylcholine	163
Figure 3-2: Neuroprotective effective of galantamine in AD.....	167
Figure 3-3: Strategies for the management of Alzheimer disease.....	197
Figure 5-1: Activation of $\alpha 7$ nicotinic acetylcholine receptors	225
Figure 5-2: NMDA receptor ion channel complex.....	229
Figure 5-3: Neurotoxicity due to misfolding of A β 1-42	268
Figure 5-4: Interactions of players in clinical trials of Alzheimer disease in the USA.....	327
Figure 5-5: Role of proteomics in drug discovery/development for Alzheimer disease	350
Figure 5-6: FDA industry interaction during drug development for AD	355
Figure 5-7: FDA's accelerated approval pathway in early Alzheimer disease	357
Figure 6-1: Unmet needs in the management of Alzheimer disease	373